High-throughput, low-cost detection of SARS-CoV-2
The SARS-CoV-2 coronavirus has created an enormous challenge for laboratories and communities worldwide. To address the crisis presented by COVID-19, labs need an accurate testing method capable of cost-effectively processing large numbers of samples.
The MassARRAY® SARS-CoV-2 Panel from Agena Bioscience® enables high-throughput, low-cost detection of COVID-19 caused by SARS-CoV-2 infection. The single-well, multiplexed assay targets 5 highly conserved regions of the viral genome, providing high accuracy and low limit of detection.
The MassARRAY SARS-CoV-2 Panel has received Emergency Use Authorization (EUA) for in vitro diagnostic use in the U.S. from the FDA. The MassARRAY SARS-CoV-2 Panel is CE-IVD marked and intended for in vitro diagnostic use in Europe. For other regions, please visit our Research Use Only Panel.
Assays by Agena scientists design, develop and functionally verify custom research use assays. Assays can be developed for targeted germline or somatic genotyping, translocations, copy number variants and methylation profiling.